IMGO Imago BioSciences, Inc.

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

$22.16  -0.45 (-1.99%)
As of 12/03/2021 10:58:17 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/16/2021
Outstanding shares:  33,528,718
Average volume:  107,443
Market cap:   $742,325,817
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45250K107
ISIN:        US45250K1079
Sedol:      BNLYJ60
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.31
PS ratio:   0.00
Return on equity:   -14.51%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy